Determine When to Add MR Antagonist in GRA Treatment
STEP 1 — Gather Information
Confirm GRA diagnosis via genetic testing (CYP11B1/CYP11B2 chimeric gene) or strong clinical/family history; document current glucocorticoid type, dose, and timing; measure seated BP and serum potassium; assess for hypokalemia or symptoms of mineralocorticoid excess.
STEP 2 — Rule In / Rule Out
Has BP normalized (systolic <140 mmHg and diastolic <90 mmHg, or age‑ and gender‑specific target) on current glucocorticoid monotherapy? If yes, continue glucocorticoid alone; if no, proceed to consider MR antagonist addition.
STEP 3 — Classify or Stratify
Classify response as glucocorticoid‑responsive (BP at target) or glucocorticoid‑nonresponsive (BP above target). For nonresponsive cases, evaluate need for MR antagonist while ensuring glucocorticoid dose is already minimized per age/weight.
STEP 4 — Decide
Add an MR antagonist: start spironolactone 12.5–25 mg once daily or eplerenone 25 mg twice daily; titrate to BP goal while checking serum potassium and creatinine every 1–2 weeks; maintain lowest effective glucocorticoid dose.
Clinical Guardrails / Mimics / Pitfalls
Monitor for hyperkalemia, especially in renal impairment or when potassium supplements are used; avoid MR antagonists in pregnancy; do not escalate glucocorticoid dose beyond physiologic replacement to prevent iatrogenic Cushing; ensure glucocorticoid is minimized before adding MR antagonist to avoid overtreatment.
Concrete Clinical Example
A 10‑year‑old with genetically confirmed GRA on prednisone 2.5 mg daily had BP 148/92 mmHg after 6 weeks; spironolactone 12.5 mg daily was added, BP improved to 122/78 mmHg and potassium remained 4.6 mmol/L after 4 weeks.
Source: The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061